Dr. Remington Nevin
Dr. Remington Nevin is a Vermont-based physician epidemiologist and expert consultant in the , particularly mefloquine (previously marketed as Lariam®) and tafenoquine (marketed as Krintafel®, Kodatef®, and Arakoda™). Dr. Nevin is and .
A former U.S. Army Major and Preventive Medicine Officer with extensive travel medicine and policy experience, Dr. Nevin serves as Executive Director of , and is a faculty associate in the Department of Mental Health at the Johns Hopkins Bloomberg School of Public Health.
Dr. Nevin’s work has been instrumental in improving policymakers’ understanding of the potential for long-lasting and permanent and , as exemplified by the recent FDA for mefloquine, and the U.S. Army Special Forces’ among . Dr. Nevin has , the , the , and the , and has provided evidence to the on the drug’s lasting neurologic and psychiatric adverse effects confounding the diagnosis and management of and . Dr. Nevin has also advocated for improvements to to better protect the health of civilian volunteers at risk of exposure to the drug.
Dr. Nevin was first to publish a clinical description of , the permanent disorder of brain and brainstem dysfunction caused by the use of mefloquine and related quinoline drugs, and to publish descriptions of certain of its , including and . Dr. Nevin has also collaborated on the first of mefloquine’s adverse effects published in the forensic psychiatry literature, and published the first of a U.S. military veteran awarded service-related disability compensation for long-lasting adverse psychiatric effects from the drug.
Dr. Nevin is available for plaintiff and defense medicolegal consultation and has successfully aided attorney clients in the U.S., Canada, Australia, New Zealand, and the European Union in reaching in cases involving claims of central nervous system injury and other adverse effects from antimalarial drugs. A current is available. Dr. Nevin is also pleased to offer his services in preparing nexus letters for veterans seeking disability compensation for injuries and illnesses arising from antimalarial exposure during military service.